Prescription medicine
Flurpiridaz f 18 Brand names: Flyrcado
Flurpiridaz f 18 (Flyrcado) is a prescription medicine with an FDA approval on record since 2024. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the flurpiridaz f 18 FDA label on DailyMed (effective July 14, 2026, GE Healthcare Inc.); the NDA 215168 record on Drugs@FDA; every flurpiridaz f 18 label on DailyMed.
Highlights of the record
FDA label of July 14, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageFLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Forms and strengths
Injection.
On the market
- Earliest approval on file
- September 27, 2024 Flyrcado, Ge Hlthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- May 13, 2042 Flyrcado injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1 through July 30, 2026
What is flurpiridaz f 18 used for?
From the label: indications and usageFLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
FDA pharmacologic class: Radioactive Diagnostic Agent.
Source: FDA drug label (Flyrcado), NDA215168 (Ge Hlthcare), as published by GE Healthcare Inc., effective July 14, 2026 (SPL set 3bb6caf8-ac98-46c7-a9f0-961e66032705), via openFDA; the full label on DailyMed
Is there a generic for flurpiridaz f 18 (Flyrcado)?
No generic flurpiridaz f 18 is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 7 patents for Flyrcado injection: the compound patent runs to May 26, 2026, and the last listed entry to May 13, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2024 earliest approval on file
- 2042 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for flurpiridaz f 18?
The FDA Adverse Event Reporting System holds 1 report that list flurpiridaz f 18 among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other radioactive diagnostic agents
- the pharmacologic class, with prices and generics
- Flurpiridaz f 18 side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other